Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

CMA approves Pharmacy2U purchase of LloydsDirect

CMA approves Pharmacy2U purchase of LloydsDirect

The regulator published its clearance decision on 12 March, with the full text of on its ruling to be published "shortly". 

The Competition and Markets Authority (CMA) has approved the purchase of LloydsDirect by Pharmacy2U following the completion of the investigations into the acquisition.


Last month, the regulator revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of Metabolic Healthcare Ltd (Lloyds Direct).

In the revocation order issued on February 12, the regulator said its decision was “based on the evidence it has received in its assessment of the Merger to date.”

The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023.

It announced that it was considering “whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK).”

The order directed the Acquirer Group and Lloyds Direct not to take any action that might lead to the integration of the businesses or transfer ownership or control of either business, except with the prior written consent of the CMA.

Further, the companies were asked to carry on businesses separately, maintaining separate sales or brand identity, and not to make any changes to the organisational structure and key staff during the investigation period.

On 23 January 2024, the CMA launched its Pharmacy2U/Lloyds Direct merger inquiry, inviting comments on the transaction from any interested party until 6 February 2024 to assist it the assessment.

Although the order has been lifted, the competition watchdog said it is ”continuing to conduct its assessment of the Merger and has not yet taken a decision.”

The CMA will announce its decision on whether to refer the case for a Phase 2 investigation on 19 March 2024.

More For You

Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less
Pharma industry group unhappy with NHS drug pricing offer

The ABPI warned that £2 billion of potential investment could be under risk

Pic credit: istock

Pharma industry group unhappy with NHS drug pricing offer

The Association of the British Pharmaceutical Industry (ABPI) has rejected the UK government’s offer to cut the cost of NHS drugs pricing scheme as it felt it was inadequate.

The industry group warned that £2 billion of potential investment could be under risk and wanted prime minister Keir Starmer to intervene, The Times reports.

Keep ReadingShow less
Day Lewis celebrates 50 years of delivering care to communities

The Patel family at the unveiling of the commemorative plaque ceremony

Day Lewis celebrates 50 years of delivering care to communities

Day Lewis honoured "the people, purpose and partnerships" as it celebrated 50 years of service by unveiling a commemorative plaque at the company’s support office in Croydon.

As one of the UK’s largest independent pharmacy chains, Day Lewis has delivered trusted care to communities across the country since it was founded in 1975, by brothers Kirit and JC Patel, who was on hand to unveil the plaque.

Keep ReadingShow less
CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

Pic credit: iStock

Pharmacy owners asked to share views on new contract and its financial implications

Pharmacy owners can share their thoughts on service developments and their financial security before the upcoming Community Pharmacy England (CPE) committee meeting to be held on June 25 and 26.

The new Community Pharmacy Contractual Framework (CPCF) was completed in March with the various service and regulatory changes still in progress.

Keep ReadingShow less
Cancer treatment impact

There have been supply issues with Creon since the summer of 2024

Pic credit: iStock

Cancer patients struggle amid digestive drug shortage

Pharmacists in the Channel Islands have revealed that there is a shortage of a drug used to support digestion in cancer patients.

Creon is a pancreatic enzyme replacement therapy (PERT), which helps people living with conditions such as cystic fibrosis, pancreatitis, and pancreatic cancer to digest food.

Keep ReadingShow less